The newly listed UltraGreen.ai has raised pressing questions among investors, analysts, and observers alike. Behind its futuristic branding, many observers believe the company is fundamentally a single-product trader attempting to ride the AI wave.

## 1. The “AI-Washing” Problem

Despite the “.ai” appended to its name, UltraGreen’s revenue engine remains tied almost entirely to a 50-year-old medical dye.

In FY2024, ICG accounted for **94.2%** of total revenue — a hallmark of over-concentration.

The touted “AI platform” is early-stage, with minimal revenue contribution. This has led many to liken the strategy to the **dot-com era**, where companies added buzzwords to inflate valuation multiples.

## 2. Supply Chain Fragility

UltraGreen has no in-house production. Instead, it depends on third-party CMOs—with its key active ingredient currently sourced primarily from **one supplier**.

This creates:

- Concentration risk

- No price control

- Operational vulnerability

A disruption in 2024 already caused months-long bottlenecks.

Critics argue that one factory incident could temporarily wipe out inventory.

## 3. Weakening Financials

UltraGreen’s recent financials show several stress indicators:

- Net margins fell from **47.7%** → **36.6%**

- FX losses totaled **US$7.0M** in 1H2025

- The IPO price implies an **82.3% dilution** relative to NAV

These trends point toward declining financial health and treasury mismanagement.

## 4. Regulatory Concerns

The prospectus discloses:

- A **“major deficiency”** flagged by Irish regulators website (HPRA)

- Liability surrounding **off-label usage**

- U.S. market restrictions due to **competitor exclusivity** until 2026

Such issues highlight heightened governance risk.

## 5. SGX Structural Risk

Industry commentary suggests the Singapore Exchange (SGX-ST) faces:

- Competency gaps in reviewing complex listings

- Over-analysis of minor issues

Critics argue this environment may enable companies to slip through with optimistic narratives despite financial red flags.

## 6. Ownership Concerns

Post-IPO, the Renew Group retains **~61.9%** control.

This means:

- Governance is effectively centralized

- Potential conflicts of interest persist due to overlapping leadership roles.

## 7. Technological & Product Obsolescence

UltraGreen’s reliance on ICG faces new threats:

- Emerging **spectral imaging** technologies that don’t require injection dyes

- A recently sold PACS business, reducing proven tech revenue

- An AI platform that the prospectus admits may contain **bugs and defects**

This raises doubts about whether the company’s pivot toward AI is sustainable or merely reactive.

## Conclusion

UltraGreen.ai’s prospectus, corporate structure, and market positioning collectively reveal a legacy business with a modern label.

Investors should approach with careful due diligence.

This analysis is based solely on the UltraGreen.ai Limited Prospectus dated 26 Nov 2025 and is provided for informational and educational purposes only.